Document is current
Any future updates will be listed below
-
Authors
Arabi, Yaseen M. https://orcid.org/0000-0001-5735-6241
Stoppe, Christian https://orcid.org/0000-0002-2028-2039
Casaer, Michael P. https://orcid.org/0000-0002-7087-0795
Ridley, Emma J. https://orcid.org/0000-0002-7922-5717
Reignier, Jean https://orcid.org/0000-0002-3768-3496
Al-Dorzi, Hasan M. https://orcid.org/0000-0002-3772-8949
Annoni, Filippo https://orcid.org/0000-0002-1271-9034
Preiser, Jean-Charles https://orcid.org/0000-0003-3163-0390
- License Information
-
More Information
Article History
Received: 4 September 2025
Accepted: 25 January 2026
First Online: 9 March 2026
Declarations
:
: YA: is the PI of the REPLENISH trial (NCT04475666). CS received honorarium as consultant and speaker fees from Fresenius, BBRAUN, Nutricia, Nestle, and Baxter. MPC receives research funding from Research Foundation—Flanders (senior clinical investigator fellowship 1832822N; project G029525N) and from the Private Charity “Help Brandwonden Kids”. Outside of the submitted work, EJR reports receiving unrestricted grants paid to my institution from Baxter Healthcare (United States), Nutricia Australia, and Fresenius Kabi Australia, as well as personal fees for speaking engagements from Nestle Australia, Baxter Healthcare (United States), Baxter Healthcare (Australia), Nutricia Australia, Fresenius Kabi, and Nestle Australia. EJR has salary support from the National Health and Medical Research Council Emerging Leadership Investigator Grant. JCP received honorarium as a consultant and speaker fees from Fresenius, Nutricia/Danone, Nestle Health Science and Baxter. JR received research funding from the French ministry of Health for the NUTRIREA-2, -3 and -4 RCTs.
